Next-generation nanovaccine induces durable immunity and protects against SARS-CoV-2
Source abstract
Abstract
While first generation SARS-CoV-2 vaccines were effective in slowing the spread and severity of disease during the COVID-19 pandemic, there is a need for vaccines capable of inducing durable and broad immunity against emerging variants of concern. Nanoparticle-based vaccines (i.e., "nanovaccines") composed of polyanhydride nanoparticles and pentablock copolymer micelles have previously been shown to protect against respiratory pathogens, including influenza A virus, respiratory syncytial virus, and Yersinia pestis. In this work, a nanovaccine containing SARS-CoV-2 spike and nucleocapsid antigens was designed and optimized. The optimized nanovaccine induced long-lived systemic IgG antibody responses against wild-type SARS-CoV-2 virus. In addition, the nanovaccine induced antibody responses capable of neutralization and cross-reactivity to multiple SARS-CoV-2 variants (including B.1.1.529) and antigen-specific CD4+ and CD8+ T cell responses. Finally, the nanovaccine protected mice against a lethal SARS-CoV-2 challenge, setting the stage for advancing particle-based SARS-CoV-2 nanovaccines. STATEMENT OF SIGNIFICANCE: First-generation SARS-CoV-2 vaccines were effective in slowing the spread and limiting the severity of COVID-19. However, current vaccines target only one antigen of the virus (i.e., spike protein) and focus on the generation of neutralizing antibodies, which may be less effective against new, circulating strains. In this work, we demonstrated the ability of a novel nanovaccine platform, based on polyanhydride nanoparticles and pentablock copolymer micelles, to generate durable and broad immunity against SARS-CoV-2. These nanovaccines induced long-lasting (> 62 weeks) serum antibody responses which neutralized binding to ACE2 receptors and were cross-reactive to multiple SARS-CoV-2 variants. Additionally, mice immunized with the SARS-CoV-2 nanovaccine showed a significant increase of antigen-specific T cell responses in the draining lymph nodes and spleens. Together, these nanovaccine-induced immune responses contributed to the protection of mice against a lethal challenge of live SARS-CoV-2 virus, indicating that this nanovaccine platform is a promising next-generation SARS-CoV-2 vaccine.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: SARS-CoV-2 and COVID-19 Research · Influenza Virus Research Studies · COVID-19 epidemiological studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (56)
Show source-provided references
1. World Health Organization, Coronavirus (COVID-19), www.who.int (2023).
2. Characteristics of SARS-CoV-2 and COVID-1910.1038/s41579-020-00459-7 ↗
3. Mechanisms of SARS-CoV-2 entry into cells10.1038/s41580-021-00418-x ↗
4. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis10.1002/path.1570 ↗
5. The SARS-coronavirus infection cycle: a survey of viral membrane proteins, their functional interactions and pathogenesis10.3390/ijms22031308 ↗
6. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness10.1038/s41586-020-2622-0 ↗
7. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates10.1056/NEJMoa2027906 ↗
8. Evidence for antibody as a protective correlate for COVID-19 vaccines10.1016/j.vaccine.2021.05.063 ↗
9. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection10.1038/s41591-021-01377-8 ↗
10. SARS-CoV-2 Omicron variant: recent progress and future perspectives10.1038/s41392-022-00997-x ↗
11. The T cell immune response against SARS-CoV-210.1038/s41590-021-01122-w ↗
12. Antibody responses in COVID-19: a review10.3389/fimmu.2021.633184 ↗
13. Encapsulation, stabilization, and release of BSA-FITC from polyanhydride microspheres10.1016/j.jconrel.2004.08.006 ↗
14. Design of an injectable system based on bioerodible polyanhydride microspheres for sustained drug delivery10.1016/S0142-9612(02)00181-3 ↗
15. Mechanistic relationships between polymer microstructure and drug release kinetics in bioerodible polyanhydrides10.1016/S0168-3659(02)00125-6 ↗
16. Single immunization with a suboptimal antigen dose encapsulated into polyanhydride microparticles promotes high titer and avid antibody responses10.1002/jbm.b.32820 ↗
17. Single dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanism10.1002/jbm.a.30545 ↗
18. Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases10.1371/journal.pone.0017642 ↗
19. Polyanhydride nanovaccines induce germinal center B cell formation and sustained serum antibody responses10.1166/jbn.2016.2242 ↗
20. Polyanhydride nanoparticles induce low inflammatory dendritic cell activation resulting in CD8(+) T cell memory and delayed tumor progression10.2147/IJN.S261041 ↗
21. Polyanhydride nanovaccine platform enhances antigen-specific cytotoxic T cell responses10.1142/S2339547814500162 ↗
22. Single dose combination nanovaccine provides protection against influenza A virus in young and aged mice10.1039/C8BM01443D ↗
23. Polyanhydride nanovaccine induces robust pulmonary B and T cell immunity and confers protection against homologous and heterologous influenza A virus infections10.3389/fimmu.2018.01953 ↗
24. Vitamin A deficiency impairs the immune response to intranasal vaccination and RSV infection in neonatal calves10.1038/s41598-019-51684-x ↗
25. Efficacy of mucosal polyanhydride nanovaccine against respiratory syncytial virus infection in the neonatal calf10.1038/s41598-018-21292-2 ↗
26. Polyanhydride-based RSV prefusion F nanoparticle vaccine establishes lasting protection mediated by humoral and cellular immune responses10.4049/jimmunol.204.Supp.166.3 ↗
27. Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague10.1016/j.actbio.2019.10.016 ↗
28. Room temperature stable PspA-based nanovaccine induces protective immunity10.3389/fimmu.2018.00325 ↗
29. Effective polymer adjuvants for sustained delivery of protein subunit vaccines10.1016/j.actbio.2014.11.050 ↗
30. Self-assembling synthetic nanoadjuvant scaffolds cross-link B cell receptors and represent new platform technology for therapeutic antibody production10.1126/sciadv.abj1691 ↗
31. Pentablock copolymer micelle nanoadjuvants enhance cytosolic delivery of antigen and improve vaccine efficacy while inducing low inflammation10.1021/acsbiomaterials.8b01591 ↗
32. Combination nanovaccine demonstrates synergistic enhancement in efficacy against influenza10.1021/acsbiomaterials.5b00477 ↗
33. The cGAS-STING defense pathway and its counteraction by viruses10.1016/j.chom.2016.01.010 ↗
34. The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response10.1016/j.actbio.2017.01.005 ↗
35. Poly[1,3-bis(p-carboxyphenoxy)-propane anhydride]
36. Synthesis and characterization of novel polyanhydrides with tailored erosion mechanisms10.1002/jbm.a.30510 ↗
37. Synthesis and optimization of next-generation low-molecular-weight pentablock copolymer nanoadjuvants10.3390/vaccines11101572 ↗
38. Novel atom transfer radical polymerization method to yield copper-free block copolymeric biomaterials10.1002/macp.201300034 ↗
39. Synthesis and characterization of temperature and pH-responsive pentablock copolymers10.1016/j.polymer.2005.05.138 ↗
40. Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants10.1172/JCI79915 ↗
41. Toll-dependent selection of microbial antigens for presentation by dendritic cells10.1038/nature04596 ↗
42. SARS-CoV-2-specific T cells in infection and vaccination10.1038/s41423-021-00743-3 ↗
43. Updated insights into the T cell-mediated immune response against SARS-CoV-2: a step towards efficient and reliable vaccines10.3390/vaccines11010101 ↗
44. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function10.1038/s41590-020-0778-2 ↗
45. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants10.1126/science.abj4176 ↗
46. Combinatorial evaluation of in vivo distribution of polyanhydride particle-based platforms for vaccine delivery
47. T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant10.1038/s41423-022-00838-5 ↗
48. Correction: mapping and role of T cell response in SARS-CoV-2–infected mice10.1084/jem.2020218710052021c ↗
49. Correlates of protection, thresholds of protection, and immunobridging among persons with SARS-CoV-2 infection10.3201/eid2902.221422 ↗
50. S. Mink, W. List, G. Hoefle, M. Frick, A. Suessenbacher, T. Winder, C. Fetz, A. Boesl, C.H. Saely, H. Drexel, P. Fraunberger, Evaluation of SARS-CoV-2 antibody levels on hospital admission as a correlate of protection against mortality, J. Intern. Med. 293(6) 694–703.10.1111/joim.13606 ↗
51. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-210.1038/s41586-021-04388-0 ↗
52. CD8+ T cells specific for conserved coronavirus epitopes correlate with milder disease in patients with COVID-1910.1126/sciimmunol.abg5669 ↗
53. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron10.1038/s41586-022-04465-y ↗
54. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron10.1016/j.cell.2022.01.015 ↗
55. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection10.1016/j.vaccine.2016.02.063 ↗
56. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-210.1016/j.cell.2022.02.005 ↗